Paclitaxel

• CAT Number: A000813
• CAS Number: 33069-62-4
• Molecular Formula: C₄₇H₅₁NO₁₄
• Molecular Weight: 853.92
• Purity: ≥95%
• Synonyms: TAXOL; Taxol A; 33069-62-4; Abraxane; Paxene
• Target: Cell Cycle/DNA Damage
• Solubility: >42.7mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
• InChI: InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
• InChIKey: RCINICONZNJXQF-MZXODVADSA-N
• SMILES: CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C

Paclitaxel（Cat No.:A000813）is a widely used chemotherapeutic agent derived from the bark of the Pacific yew tree, known for its potent antitumor properties. It functions by stabilizing microtubules and preventing their depolymerization, thereby disrupting the normal cell cycle and inducing apoptosis in rapidly dividing cancer cells. Paclitaxel is effective against various malignancies, including breast, ovarian, and lung cancers. Despite its effectiveness, it is associated with side effects such as myelosuppression, neuropathy, and hypersensitivity reactions. Ongoing research seeks to enhance its efficacy and reduce toxicity through improved formulation and combination therapies.

Reference

1: Van Cutsem E, Bang YJ, Mansoor W, Petty RD, Chao Y, Cunningham D, Ferry DR, Smith NR, Frewer P, Ratnayake J, Stockman PK, Kilgour E, Landers D. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann Oncol. 2017 Jun 1;28(6):1316-1324. doi: 10.1093/annonc/mdx107. PubMed PMID: 29177434.
2: Lv KT, Gao LJ, Hua X, Li F, Gu Y, Wang W. The role of the globular heads of the C1q receptor in paclitaxel-induced human ovarian cancer cells apoptosis by a mitochondria-dependent pathway. Anticancer Drugs. 2017 Nov 23. doi: 10.1097/CAD.0000000000000567. [Epub ahead of print] PubMed PMID: 29176398.
3: Bhatt P, Lalani R, Vhora I, Patil S, Amrutiya J, Misra A, Mashru R. Liposomes encapsulating native and cyclodextrin enclosed Paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation. Int J Pharm. 2017 Nov 22. pii: S0378-5173(17)31103-1. doi: 10.1016/j.ijpharm.2017.11.048. [Epub ahead of print] PubMed PMID: 29175440.
4: Saito S, Muneoka Y, Ishikawa T, Akazawa K. Cost-Effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-Line Chemotherapy in Japan. Clin Ther. 2017 Nov 23. pii: S0149-2918(17)31057-3. doi: 10.1016/j.clinthera.2017.10.017. [Epub ahead of print] PubMed PMID: 29175097.
5: Yamamoto E, Watanabe S, Bao B, Watanabe H, Nakatsuma K, Izuhara M, Ono K, Nakazawa G, Kimura T, Saito N. Preclinical evaluation of a paclitaxel-incorporated nanoparticle-coated balloon in rabbit and porcine models. Cardiovasc Revasc Med. 2017 Oct 19. pii: S1553-8389(17)30397-4. doi: 10.1016/j.carrev.2017.10.007. [Epub ahead of print] PubMed PMID: 29174499.
6: Miles D, Cameron D, Hilton M, Garcia J, O/'Shaughnessy J. Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer. Eur J Cancer. 2017 Nov 23. pii: S0959-8049(17)31358-8. doi: 10.1016/j.ejca.2017.10.018. [Epub ahead of print] PubMed PMID: 29174181.
7: Wong YN, Manola J, Hudes GR, Roth BJ, Moul JW, Barsevick AM, Scher RM, Volk MJ, Vaughn DJ, Williams SD, Fisch MJ, Cella D, Carducci MA, Wilding G. Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial. Clin Genitourin Cancer. 2017 Oct 16. pii: S1558-7673(17)30307-5. doi: 10.1016/j.clgc.2017.10.001. [Epub ahead of print] PubMed PMID: 29173976.
8: Phan NH, Ly TT, Pham MN, Luu TD, Vo TV, Tran PH, Tran TT. A comparison of fucoidan conjugated to paclitaxel and curcumin for the dual delivery of cancer therapeutic agents. Anticancer Agents Med Chem. 2017 Nov 21. doi: 10.2174/1871520617666171121125845. [Epub ahead of print] PubMed PMID: 29173183.
9: Steins A, Ebbing EA, Pistorius MCM, Waasdorp C, Krishnadath KK, Medema JP, Wilmink JW, Mathôt RAA, Bijlsma MF, van Laarhoven HWM. Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel. Drug Deliv. 2017 Nov;24(1):1801-1810. doi: 10.1080/10717544.2017.1406559. PubMed PMID: 29172757.
10: Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol. 2017 Nov 20. pii: S1470-2045(17)30694-0. doi: 10.1016/S1470-2045(17)30694-0. [Epub ahead of print] PubMed PMID: 29169877.